Compare · BSX vs PETV
BSX vs PETV
Side-by-side comparison of Boston Scientific Corporation (BSX) and PetVivo Holdings Inc. (PETV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and PETV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 5162.0x PETV ($12.4M).
- PETV has been more active in the news (6 items in the past 4 weeks vs 5 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 1 for PETV).
- Company
- Boston Scientific Corporation
- PetVivo Holdings Inc.
- Price
- $44.38+0.50%
- $1.02-4.67%
- Market cap
- $63.97B
- $12.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
PetVivo Holdings Inc.
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest PETV
- PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES
- PetVivo Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PetVivo Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Michael Handley Joins PetVivo Holdings, Inc. Board of Directors
- Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors
- Director Rudelius Robert James was granted 3,497 shares, increasing direct ownership by 0.87% to 406,889 units (SEC Form 4)
- PETVIVO ANIMAL HEALTH, INC. RELEASES CONFERENCE AND EXHIBIT SCHEDULE FOR 2026-2027
- Large owner A.L. Sarroff Fund, Llc bought $40,022 worth of shares (58,602 units at $0.68) (SEC Form 4)
- Amendment: Chief Financial Officer Lowenthal Garry N was granted 31,250 shares (SEC Form 4)
- Amendment: Chief Executive Officer Lai John was granted 31,250 shares, increasing direct ownership by 1% to 2,413,163 units (SEC Form 4)